Medical devices, healthcare technology and the business of care
PMA approval · P980044

SUPARTZ FX

Seikagaku Corp. · Decision date Jan 24, 2001

MEDTECHLEDGER EXPLANATIONP980044

What did the FDA approve?

FDA database entry P980044 records an approval decision dated January 24, 2001, for SUPARTZ FX from Seikagaku Corp. The decision statement identifies the device as the SUPARTZ(TM) Dispo and states its indication: treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen.

The entry lists the device category as acid, hyaluronic, intraarticular, the product code as MOZ, and the specialty as orthopedic. The statement reports the approved indication but does not provide independent evidence of safety or clinical effectiveness. No supplement type or supplement reason is recorded, so the entry does not indicate whether this decision modified a prior submission.

FDA approval order statement

APPROVAL FOR THE SUPARTZ(TM) DISPO. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Jan 24, 2001

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980044
Regulatory pathway
Premarket approval application
Product code
MOZ
Decision code
APPR
Decision date
Jan 24, 2001
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P980044 received

    Application receipt date recorded by FDA.

  2. P980044 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P980044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980044

Product / regulatory recordCompanyPathwayDecision dateSource
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
GEL-ONEP080020
Seikagaku Corp.PMA approvalMar 22, 2011FDA
Ferring Pharmaceuticals, Inc.PMA approvalDec 3, 2004FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Seikagaku Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records